s-equol
Small moleculeexperimental
Equol (4',7-isoflavandiol) is an isoflavandiol estrogen metabolized from daidzein, a type of isoflavone found in soybeans and other plant sources, by bacterial flora in the intestines. While endogenous estrogenic hormones such as estradiol are steroids, equol is a nonsteroidal estrogen. Only about 30–50% of people have intestinal bacteria that make equol. — Wikipedia
Clinical trial activity
12 trials · 14 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2008 (NCT00787007)
Timeline
Indications
Studied for
- Acne Vulgaris · Phase 1/Phase 2
- Alzheimer Disease · Phase 1/Phase 2
- Breast Neoplasms · Early Phase 1
- Cognitive Dysfunction · Phase 2
- Healthy Volunteers · Phase 1
- Menopause · Phase 2
- Prostatic Hyperplasia · Phase 2
- Renal Insufficiency, Chronic · Phase 2
- Vascular Diseases · Phase 2
- Vascular Stiffness · Phase 2
- White Matter · Phase 2
- Women · Phase 2
Mechanism of action
- Estrogen receptor betaAGONIST
ESR2 agonist
Chemistry & pharmacology
Loading structure…
SMILES
Oc1ccc([C@H]2COc3cc(O)ccc3C2)cc1- Mol. weight
- 242.27 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEquol ↗
- ChEMBLCHEMBL198877 ↗
Also known as
- aus-131
- aus-131
- equol
- equol
- equol
- equol
- (s)-equol
- (s)-equol
- s-equol
- s-equol
- s-equol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05741060 | Phase 2 | Jun 29, 2023 | National Institute on Aging (NIA), University of Pittsburgh |
| NCT06128278 | Phase 2 | Mar 7, 2023 | University of Colorado, Denver |
| NCT04516304 | N/A | Mar 27, 2019 | Biofortis, Pharmavite |
| NCT03101085 | Phase 1/Phase 2 (Phase 2) | May 5, 2017 | Ausio Pharmaceuticals, LLC, University of Kansas |
| NCT02515682 | N/A | Oct 1, 2015 | Chinese University of Hong Kong |
| NCT02352025 | Early Phase 1 (Phase 1) | Apr 1, 2015 | University of Texas, San Antonio |
| NCT02142777 | Phase 1 | Jul 1, 2014 | Ausio Pharmaceuticals, LLC, University of Kansas |
| NCT01301586 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2010 | Avail Clinical Research, Nexgen Pharma, Inc |
| NCT00962585 | Phase 2 | Jun 1, 2010 | Ausio Pharmaceuticals, LLC, University of Cincinnati |
| NCT00962390 | Phase 2 | Jun 1, 2009 | Ausio Pharmaceuticals, LLC, Tampa Bay Medical Research |
| NCT00998920 | Phase 1 | Dec 1, 2008 | Ausio Pharmaceuticals, LLC, INC Research |
| NCT00787007 | Phase 1 | Sep 1, 2008 | Ausio Pharmaceuticals, LLC |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (14)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ausio Pharmaceuticals, LLC | For profit | 6 | 4 | 2 | 2008 |
| University of Kansas | Academic/Hospital | 2 | 2 | 2 | 2014 |
| Avail Clinical Research | For profit | 1 | 0 | 1 | 2010 |
| Biofortis | For profit | 1 | 0 | 1 | 2019 |
| Chinese University of Hong Kong | Academic/Hospital | 1 | 1 | 1 | 2015 |
| INC Research | For profit | 1 | 0 | 1 | 2008 |
| National Institute on Aging (NIA) | Government | 1 | 0 | 1 | 2023 |
| Nexgen Pharma, Inc | For profit | 1 | 1 | 1 | 2010 |
| Pharmavite | For profit | 1 | 1 | 1 | 2019 |
| Tampa Bay Medical Research | For profit | 1 | 0 | 1 | 2009 |
| University of Cincinnati | Academic/Hospital | 1 | 0 | 1 | 2010 |
| University of Colorado, Denver | Academic/Hospital | 1 | 1 | 1 | 2023 |
| University of Pittsburgh | Academic/Hospital | 1 | 1 | 1 | 2023 |
| University of Texas, San Antonio | Academic/Hospital | 1 | 1 | 1 | 2015 |
14 organizations
Page 1 / 1